What is the present valuation and projected CAGR of the aspergillosis treatment market?
The aspergillosis treatment market size has grown strongly in recent years. It will grow from $3.14 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to diagnostic advancements, demand for antifungal medications, increased incidence, invasive procedures.
The aspergillosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.28 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to demand for transplant medicine, prevalence of hematologic malignancies, increasing investments in research and development, public health initiatives. Major trends in the forecast period include antifungal resistance, targeted therapies, therapeutic drug monitoring, drug development.
Get Your Free Sample of The Global Aspergillosis Treatment Market Report:
What key drivers have fueled the aspergillosis treatment market’s development over the years?
The increasing prevalence of fungal infections is expected to propel the growth of the aspergillosis treatment market going forward. Fungal infections, also known as mycosis, are diseases caused by fungi. It can also cause infections in humans and animals. Aspergillosis is a fungal infection that affects various body parts, including the respiratory system, lungs, brain, kidneys and other organs. Aspergillosis treatment, such as voriconazole, aims to control the fungal infection, alleviate symptoms, prevent complications and improve overall health. For instance, in September 2023, according to The Health Security Agency, a UK-based government agency, bloodstream infection due to yeast per 100,000 population in England increased from 3.8 in 2021 to 4.0 in 2022. Therefore, the increasing prevalence of fungal infections is driving the growth of the aspergillosis treatment market.
What is the segmentation for the aspergillosis treatment market?
The aspergillosis treatment market covered in this report is segmented –
1) By Type: Allergic Aspergillosis, Chronic Aspergillosis, Invasive Aspergillosis, Other Type
2) By Drug Class: Corticosteroids, Antifungal drugs, Other Drug Class
3) By Route of Administration: Oral, Injectable, Other Route Of Administration
4) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Other Distribution Channel
Subsegments:
1) By Allergic Aspergillosis: Allergic Fungal Sinusitis, Allergic Bronchopulmonary Aspergillosis (ABPA)
2) By Chronic Aspergillosis: Chronic Pulmonary Aspergillosis, Chronic Cavitary Aspergillosis
3) By Invasive Aspergillosis: Pulmonary Invasive Aspergillosis, Disseminated Invasive Aspergillosis
4) By Other Type: Aspergilloma, Other Rare Forms of Aspergillosis
Order your report now for swift delivery
Who are the most influential companies in the aspergillosis treatment market?
Major companies operating in the aspergillosis treatment market are Basilea Pharmaceutica Ltd., Pfizer Inc., Johnson and Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, Astellas Pharma Inc., Regeneron Pharmaceuticals, Mylan N.V., Sun Pharmaceutical Industries, Jazz Pharmaceuticals, Dr. Reddy’s Laboratories, Cipla Ltd., Bruker Corporation, Hikma Pharmaceuticals PLC.
What are the top industry trends projected to impact the aspergillosis treatment market?
Major companies operating in the aspergillosis treatment market are focused on introducing innovative aspergillosis drugs and solutions to sustain their position in the market. Drug development increases treatment options for aspergillosis, such as posaconazole oral suspension that provides more targeted and effective treatment options for patients. For instance, in April 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched Posaconazole oral suspension in the US for aspergillosis treatment. These drugs apply to patients at high risk of contracting invasive aspergillus and candida infections as they have severely compromised immune systems, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD). Oropharyngeal candidiasis (OPC), especially OPC refractory (OPC) to itraconazole and fluconazole, is another condition for which posaconazole oral suspension is recommended.
What are the major regional insights for the aspergillosis treatment market, and which region holds the top position?
North America was the largest region in the aspergillosis treatment market in 2024. The regions covered in aspergillosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Aspergillosis Treatment Market Report 2025 Offer?
The aspergillosis treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Aspergillosis treatment refers to treating a fungal infection caused by the aspergillus species and its treatment depends on the severity and type of disease. Aspergillosis can be a severe and potentially life-threatening condition, especially in individuals with weakened immune systems.
Purchase the exclusive report now to unlock valuable market insights:
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: http://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
